Is REGN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Regeneron Pharmaceuticals (REGN) rests on Dupixent keeps compounding: Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. The bear case rests on the clearest risk is Eylea biosimilar erosion. Analysts covering it publish targets from $641.00 to $1000.00 against a $697.05 price, so even the professionals disagree by 44% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Regeneron was founded in 1988 by Leonard Schleifer, who remains a central leader, with chief scientific officer George Yancopoulos shaping its science-first culture. The company built its reputation on proprietary VelociSuite antibody-discovery technologies and the Regeneron Genetics Center, an internal engine that turns large-scale human genetics into drug targets. That R&D productivity, rather than acquisitions, has historically driven its growth. In 2025 the board initiated its first quarterly dividend and expanded share repurchases, signaling a more mature capital-return posture alongside heavy ongoing R&D investment.
The bull case: what would have to be true for $1000.00
The most optimistic published target on REGN is $1000.00, +43.5% from the $697.05 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
Dupixent keeps compounding
Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. Because Regeneron splits economics with Sanofi, growth flows through as rising collaboration revenue. As long as new indications and geographies keep landing, this franchise can offset pressure elsewhere in the portfolio.
A deep, diversified pipeline
Regeneron carries nearly 50 clinical candidates across roughly six therapeutic areas, including hematology-oncology, complement-mediated diseases, and anticoagulation. The company also logged its first gene therapy approval, signaling expansion beyond antibodies. This breadth means the investment case does not rest on any single readout, though individual trials still carry binary outcomes.
R&D productivity as a moat
The VelociSuite platform and Regeneron Genetics Center give the company an internal discovery engine that has repeatedly produced approved medicines without relying on large acquisitions. Planned R&D investment of roughly $6.6 billion in 2026 reflects management's bet that this engine keeps generating the next franchises. Investors who value durable innovation tend to anchor on this capability rather than any one drug.
Oncology optionality
Libtayo anchors a growing oncology effort, with fianlimab and other programs advancing in late-stage development. Oncology could become a third major pillar alongside immunology and eye disease over time. It is earlier in its revenue contribution, so it represents upside optionality more than a current cash driver.
The bear case: what would have to be true for $641.00
The most pessimistic published target is $641.00, -8.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Regeneron Pharmaceuticals is worth if the risks below bite instead of the drivers above.
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding REGN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on REGN
26 analysts cover REGN, with an average target of $819.25 (+17.5% against $697.05) and a split of 18 buy, 9 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the REGN forecast and price target page.
How is REGN valued? (as of June 27, 2026)
Snapshot for REGN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Total revenue (TTM, approx): ~$14 billion
- Q1 2026 total revenue: ~$3.6 billion (up ~19% YoY)
- Dupixent global net sales (Q1 2026): ~$4.9 billion (up ~31%)
- Eylea + Eylea HD U.S. net sales (Q1 2026): ~$941 million combined
- Cash and marketable securities (approx): ~$17 billion
- P/E (approx): ~15x
- Market capitalization (approx): ~$66 billion
Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.
How do you decide if REGN is a buy?
Rather than asking whether REGN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold REGN indirectly through an index or sector ETF before adding more.
What would change your mind on REGN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Dupixent keeps compounding stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the clearest risk is Eylea biosimilar erosion fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the REGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about REGN against your real portfolio and see your actual exposure before deciding.
Investing in Regeneron Pharmaceuticals with AI
Connect the broker you already use and ask Walnut's AI how REGN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is REGN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Dupixent keeps compounding, with total revenue (ttm, approx) at ~$14 billion. The bear case rests on the clearest risk is Eylea biosimilar erosion. Analysts covering it are spread from $641.00 to $1000.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell REGN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The clearest risk is Eylea biosimilar erosion. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $641.00, -8.0% from the $697.05 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for REGN?
+
Dupixent keeps compounding. Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. The most optimistic analyst target on REGN is $1000.00, +43.5% from the $697.05 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for REGN?
+
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics. The most pessimistic published target is $641.00, -8.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Regeneron Pharmaceuticals do?
+
Regeneron makes money primarily through two large franchises.
What would have to change for REGN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Dupixent keeps compounding) stalling in the reported numbers rather than in the narrative, the risk above (the clearest risk is Eylea biosimilar erosion) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Is REGN a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is Dupixent growth plus a productive R&D engine and deep pipeline. The bear case is accelerating Eylea biosimilar erosion and franchise concentration. A long-term investor comfortable with biotech volatility weighs those differently than someone needing near-term stability. Consider how REGN fits your overall portfolio and existing healthcare exposure.
What does Regeneron do?
+
Regeneron is a biotechnology company that discovers, develops, and sells medicines. Its largest products are Dupixent for inflammatory diseases such as eczema and asthma (partnered with Sanofi), and Eylea and Eylea HD for retinal eye diseases. It also markets Libtayo in oncology and runs a broad pipeline built on its VelociSuite discovery platform and the Regeneron Genetics Center.
Does REGN pay a dividend?
+
Yes. Regeneron initiated its first quarterly cash dividend in 2025, declaring $0.88 per share, alongside expanded share repurchases. The dividend yield is small, roughly half a percent, so REGN is primarily a growth-oriented holding rather than an income stock. Most of its shareholder return historically came through buybacks and share-price appreciation rather than dividend payments.
Walnut is informational, not investment advice, and gives no verdict on REGN. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature REGN
REGN is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.